New mechanism behind breast cancer metastasis uncovered
June 30, 2026
In the new study, the researchers show that METTL3 in breast cancer cells relocates from its usual location in the nucleus to the cytoplasm.
In the new study, the researchers show that METTL3 in breast cancer cells relocates from its usual location in the nucleus to the cytoplasm.
Researchers report encouraging early results from a first-in-human clinical trial led by Children’s National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors.
Biomedical engineers at Duke University have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel cells critical to retinal health for the first time.
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has been demonstrated by researchers at the University of Bath in the U.K.
A recent study found that a blood protein called GDF15, which is released when cells are under stress, could serve as one of the earliest warning signs of dementia.
BLOOMINGTON, Minn., June 30, 2026 /PRNewswire/ — Saluda Medical, Inc. (ASX: SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Saluda’s CAP24 paddle lead, allowing it to be marketed and sold in the U.S.
Powassan virus spreads through infected ticks, raising concern in Maine and Rhode Island, and symptoms can make the infection dangerous.
New study finds biomarkers that may someday help clinicians better detect—and possibly cure—early and persistent Borrelia burgdorferi infections
Sensitive test looking for key genetic mutation detects high-risk patients missed by standard testing
Aurenar announced today that it received FDA breakthrough device designation for its V-Link noninvasive neuromodulation system.